Skip to main content

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Publication ,  Journal Article
Zhang, S; Gu, C; Huang, L; Wu, H; Shi, J; Zhang, Z; Zhou, Y; Zhou, J; Gao, Y; Liu, J; Leng, Y; Liu, X; Zhang, Q; Huang, L; Tong, X; Li, J ...
Published in: Sci Rep
June 21, 2022

CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present study, we developed second-generation (CD28z) and third-generation (CD28BBz) CAR T-cells targeting CD30 and investigated their efficacy in vitro and in vivo. Both of CD28z and CD28BBz anti-CD30 CAR T cells were similar regarding amplification, T cell subsets distribution, T cell activity, effector/memory and exhaustion. However, we found that the 28BBz anti-CD30 CAR T-cells persist long-term, specifically homing to the tumor and mediating powerful antitumor activity in tumor xenograft models. Subsequently, we also demonstrated that the third generation anti-CD30 CAR T-cells have miner side effects or potential risks of tumorigenesis. Thus, anti-CD30 CAR T-cells represent a safe and effective treatment for Hodgkin lymphoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Rep

DOI

EISSN

2045-2322

Publication Date

June 21, 2022

Volume

12

Issue

1

Start / End Page

10488

Location

England

Related Subject Headings

  • T-Lymphocytes
  • Lymphoma, Large-Cell, Anaplastic
  • Ki-1 Antigen
  • Immunotherapy, Adoptive
  • Humans
  • Hodgkin Disease
  • Antibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, S., Gu, C., Huang, L., Wu, H., Shi, J., Zhang, Z., … Zhang, T. (2022). The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep, 12(1), 10488. https://doi.org/10.1038/s41598-022-14523-0
Zhang, Shangkun, Chaojiang Gu, Lifang Huang, Han Wu, Jiangzhou Shi, Zijian Zhang, Yong Zhou, et al. “The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.Sci Rep 12, no. 1 (June 21, 2022): 10488. https://doi.org/10.1038/s41598-022-14523-0.
Zhang S, Gu C, Huang L, Wu H, Shi J, Zhang Z, et al. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep. 2022 Jun 21;12(1):10488.
Zhang, Shangkun, et al. “The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.Sci Rep, vol. 12, no. 1, June 2022, p. 10488. Pubmed, doi:10.1038/s41598-022-14523-0.
Zhang S, Gu C, Huang L, Wu H, Shi J, Zhang Z, Zhou Y, Zhou J, Gao Y, Liu J, Leng Y, Liu X, Zhang Q, Tong X, Young KH, Li J, Zhu H, Zhang T. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep. 2022 Jun 21;12(1):10488.

Published In

Sci Rep

DOI

EISSN

2045-2322

Publication Date

June 21, 2022

Volume

12

Issue

1

Start / End Page

10488

Location

England

Related Subject Headings

  • T-Lymphocytes
  • Lymphoma, Large-Cell, Anaplastic
  • Ki-1 Antigen
  • Immunotherapy, Adoptive
  • Humans
  • Hodgkin Disease
  • Antibodies